AIM ImmunoTech (LTS:0A4Y) EPS (Basic) : $-0.31 (TTM As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is AIM ImmunoTech EPS (Basic)?

AIM ImmunoTech's basic earnings per share (Basic EPS) for the three months ended in Dec. 2024 was $-0.10. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.31.

AIM ImmunoTech's EPS (Diluted) for the three months ended in Dec. 2024 was $-0.10. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.31.

AIM ImmunoTech's EPS without NRI for the three months ended in Dec. 2024 was $-0.10. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was -0.30.

During the past 3 years, the average EPS without NRI Growth Rate was 1.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 26.70% per year. During the past 10 years, the average EPS without NRI Growth Rate was 44.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, AIM ImmunoTech's highest 3-Year average EPS without NRI Growth Rate was 70.20% per year. The lowest was -19.70% per year. And the median was 12.60% per year.

AIM ImmunoTech EPS (Basic) Historical Data

The historical data trend for AIM ImmunoTech's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech EPS (Basic) Chart

AIM ImmunoTech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

Get a 7-Day Free Trial

-0.45

-0.40

-0.60

-0.31

AIM ImmunoTech Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EPS (Basic)	Get a 7-Day Free Trial															-0.26	-0.12	-0.03	-0.06	-0.10

AIM ImmunoTech EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

AIM ImmunoTech's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-17.32	-	0)	/	56.017
	=	-0.31

AIM ImmunoTech's Basic EPS for the quarter that ended in Dec. 2024 is calculated as

Basic EPS (Q: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-5.967	-	0)	/	64.013
	=	-0.09

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.31

AIM ImmunoTech (LTS:0A4Y) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

AIM ImmunoTech EPS (Basic) Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

AIM ImmunoTech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (LTS:0A4Y) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

AIMI:USA HXB2:Germany

Address

2117 SW Highway 484, Ocala, FL, USA, 34473

Website

https://www.aimimmuno.com

AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).

AIM ImmunoTech Headlines

No Headlines